Health and Healthcare

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

143 Articles

Chris Lange | Nov 3, 2017 at 11:10 AM EDT

Sarepta Takes Another Big Step Forward With DMD Treatment

Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a…

Chris Lange | Oct 4, 2017 at 10:56 AM EDT

Amicus Therapeutics Wins Big at World Muscle Society Conference

Amicus Therapeutics is another biotech player seeing a nice boost from the World Muscle Society Conference in France.

Chris Lange | Oct 4, 2017 at 10:10 AM EDT

Why Catabasis Shares Are Surging

Catabasis Pharmaceuticals shares continued their incredible climb after the announcement of positive efficacy results from its MoveDMD trial in a…

Chris Lange | Oct 2, 2017 at 1:40 PM EDT

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade…

Jon C. Ogg | Oct 2, 2017 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: AbbVie, Baker Hughes, CSX, Micron, Nucor, PepsiCo, Western Digital and More

courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one…

Chris Lange | Sep 30, 2017 at 8:20 AM EDT

Major Biotech, Pharma and FDA Catalysts Coming in October

24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.

Chris Lange | Sep 6, 2017 at 10:15 AM EDT

Sarepta Therapeutics Surges Following Duchenne Muscular Dystrophy Trial

Sarepta Therapeutics saw its shares make a handy gain on Wednesday after the firm announced muscle biopsy results from its…

Lee Jackson | Apr 5, 2017 at 9:15 AM EDT

Top Analyst Upgrades and Downgrades: AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor, Wynn and More

Wednesday’s top analyst upgrades, downgrades and initiations included AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor and Wynn Resorts,

Lee Jackson | Jan 19, 2017 at 8:40 AM EST

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the…

Chris Lange | Jan 10, 2017 at 3:30 PM EST

Tuesday’s Top Biopharma Movers

Considering the new Trump administration, there is an increasingly positive sentiment in the health care sector. In the past year,…

Jon C. Ogg | Jan 3, 2017 at 9:05 AM EST

Top Analyst Upgrades and Downgrades: Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone, Sarepta and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone and Sarepta.

Trey Thoelcke | Dec 30, 2016 at 11:15 AM EST

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.

Jon C. Ogg | Dec 14, 2016 at 8:35 AM EST

Top Analyst Upgrades and Downgrades: CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm, Xilinx and More

The top analyst upgrades, downgrades and initiations seen on Wednesday morning include CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm and Xilinx.

Chris Lange | Oct 4, 2016 at 10:35 AM EDT

Summit Therapeutics Skyrockets on Sarepta Deal

Shares of Summit Therapeutics more than doubled on Tuesday after it was announced that it would be entering into a…

Chris Lange | Oct 2, 2016 at 10:05 AM EDT

Top 6 Biopharma Gainers of the Past Week

Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood…

1 … 3 4 5 6 7 … 10

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Sarepta Takes Another Big Step Forward With DMD Treatment

Amicus Therapeutics Wins Big at World Muscle Society Conference

Why Catabasis Shares Are Surging

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Top Analyst Upgrades and Downgrades: AbbVie, Baker Hughes, CSX, Micron, Nucor, PepsiCo, Western Digital and More

Major Biotech, Pharma and FDA Catalysts Coming in October

Sarepta Therapeutics Surges Following Duchenne Muscular Dystrophy Trial

Top Analyst Upgrades and Downgrades: AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor, Wynn and More

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

Tuesday’s Top Biopharma Movers

Top Analyst Upgrades and Downgrades: Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone, Sarepta and More

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Top Analyst Upgrades and Downgrades: CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm, Xilinx and More

Summit Therapeutics Skyrockets on Sarepta Deal

Top 6 Biopharma Gainers of the Past Week

Why High-Earning Pilots Should Delay 401(k) Roth Conversions Until After Mandatory Retirement at 65

The $1,000 Hidden Tax on Every $10,000 Invested in This NVIDIA ETF

Everyone’s Chasing The Villages. Smart Retirees Are Quietly Buying Here Instead

Why High-Earning Pilots Should Delay 401(k) Roth Conversions Until After Mandatory Retirement at 65

Everyone's Chasing The Villages. Smart Retirees Are Quietly Buying Here Instead

Why High-Earning Pilots Should Delay 401(k) Roth Conversions Until After Mandatory Retirement at 65

The $1,000 Hidden Tax on Every $10,000 Invested in This NVIDIA ETF

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Sarepta Takes Another Big Step Forward With DMD Treatment

Amicus Therapeutics Wins Big at World Muscle Society Conference

Why Catabasis Shares Are Surging

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Top Analyst Upgrades and Downgrades: AbbVie, Baker Hughes, CSX, Micron, Nucor, PepsiCo, Western Digital and More

Major Biotech, Pharma and FDA Catalysts Coming in October

Sarepta Therapeutics Surges Following Duchenne Muscular Dystrophy Trial

Top Analyst Upgrades and Downgrades: AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor, Wynn and More

Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential

Tuesday’s Top Biopharma Movers

Top Analyst Upgrades and Downgrades: Abercrombie, Nokia, Disney, Xerox, Verizon, Vodafone, Sarepta and More

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Top Analyst Upgrades and Downgrades: CONSOL Energy, Kroger, 3M, NVIDIA, Qualcomm, Xilinx and More

Summit Therapeutics Skyrockets on Sarepta Deal

Top 6 Biopharma Gainers of the Past Week

Why High-Earning Pilots Should Delay 401(k) Roth Conversions Until After Mandatory Retirement at 65

The $1,000 Hidden Tax on Every $10,000 Invested in This NVIDIA ETF

Everyone’s Chasing The Villages. Smart Retirees Are Quietly Buying Here Instead

Featured Reads

Why High-Earning Pilots Should Delay 401(k) Roth Conversions Until After Mandatory Retirement at 65

Everyone's Chasing The Villages. Smart Retirees Are Quietly Buying Here Instead